drugset / Trial / NCT05152004

Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment

NCT05152004

Completed 240 enrolled Chang Gung Memorial Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of H. pylori infection. This study aims to better understand the potential of both hybrid and igh-dose dual therapies in the treatment of H. pylori infection. .

Timeline

Start
2018-09-01
Primary completion
2021-11-30
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 750 mg
Subject Amoxicillin Other / unclassified 1 g
Comparator Clarithromycin Small molecule 500 mg
Comparator Metronidazole Small molecule 500 mg
Subject Rabeprazole Small molecule 20 mg